CD304 (BDCA-4) Antibody, anti-human, APC-Vio® 770, REAfinity™ 130-111-896 from Miltenyi Biotec

Product Specs
ItemCD304 (BDCA-4) Antibody, anti-human, APC-Vio® 770, REAfinity™
CompanyMiltenyi Biotec
Price Pricing Info Supplier Page View Company Product Page
Catalog Number130-111-896
Quantity100 tests in 200 µL
ApplicationsFlow cytometry
Conjugate/TagAPC-Vio 770
FormatReagents are supplied in buffer containing stabilizer and 0.05% sodium azide
IsotypeIgG1
CloneREA774
Hosthuman cell line
Antibody TypePrimary antibodies, Recombinant antibodies
NCBI Full Gene Nameneuropilin 1
NCBI Gene AliasesBDCA4, CD304, NP1, NRP, VEGF165R
Clonalitymonoclonal
Reactivityhuman
Concentration1:50
ModificationsRecombinantly engineered
TargetCD304 (BDCA-4)
Research AreaFor research use only
Regulatory StatusFor research use only

Local Office

Miltenyi Biotec Inc.

2303 Lindbergh Street

Auburn, CA 95602

United States

Phone: Phone: +1 530 888 8871
Toll Free: 800 FOR MACS
Fax: +1 530 888 8925

Email: macs@miltenyibiotec.com

International Office

Miltenyi Biotec B.V. & Co. KG

Friedrich-Ebert-Straße 68

51429 Bergisch Gladbach

Germany

Phone: +49 2204 8306-0
Fax: +49 2204 8306-235

Email: macs@miltenyibiotec.de

(1) Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapyClinical cancer research : an official journal of the American Association for Cancer ResearchAugust 1, 2013Federica Moschella, Giovanni Fernando Torelli, Mara Valentini, Francesca Urbani, Carla Buccione, Maria Teresa Petrucci, Fiammetta Natalino, Filippo Belardelli, Robin Foà, Enrico Proietti

(3) Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health statusJournal of immunology (Baltimore, Md. : 1950)June 1, 2011Mittag D, Proietto AI, Loudovaris T, Mannering SI, Vremec D, Shortman K, Wu L, Harrison LC.

(4) Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensThe Journal of experimental medicineJune 7, 2010Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, et al.

(5) Plasmacytoid dendritic cells: from specific surface markers to specific cellular functionsHuman immunologyDecember 1, 2002Dzionek A, Inagaki Y, Okawa K, Nagafune J, Röck J, Sohma Y, Winkels G, Zysk M, Yamaguchi Y, Schmitz J.

(6) BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta inductionThe Journal of experimental medicineDecember 17, 2001Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, Günther G, Johnston I, Lanzavecchia A, Nagasaka T, et al.

(7) BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral bloodJournal of immunology (Baltimore, Md. : 1950)December 1, 2000Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck DW, Schmitz J.

(8) Dendritic cells: multi-lineal and multi-functionalImmunology todaySeptember 1, 2000Grabbe S, Kämpgen E, Schuler G.

CD304 (BDCA-4) Antibody, anti-human, APC-Vio® 770, REAfinity™ from Miltenyi Biotec